Results 231 to 240 of about 1,016,542 (305)

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Early Outcomes of an Extended Postpartum Hypertension Program: Care Beyond Delivery. [PDF]

JACC Case Rep
Nadeau C, Pressman K, Ellis L, Nuñez Pellot C, Swope A, Young A, Cain MA, Crousillat DR.   +7 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Influence of comorbidities, geriatric syndromes, and frailty on mortality risk by discharge destination in older adults after acute hospitalization: a nationwide cohort study. [PDF]

Front Public Health
Kim S, Lee JR, Kim K, Park J, Lee K, Koo HY, Cho E, Lee H.   +7 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

How to Fix a Broken Health Care System: Pathways to Maximize Health and Well-being for All. [PDF]

Diabetes Care
Chin MH, Bruch JD, Grogan CM, Huang ES, Kandula NR, Kim DD, Peek ME, Pollack HA.   +7 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source

Unexpected consequences of community-based integrated care services reform: increased hospitalization expenses among older adults in China, 2011-2018. [PDF]

Front Public Health
Xin J, Han L.
europepmc   +1 more source

Access to Healthcare for Hydrocephalus in the United States: Analyzing the Hydrocephalus Association Patient-Powered Interactive Engagement Registry (HAPPIER). [PDF]

Risk Manag Healthc Policy
Miller KH, Lanjewar SN, Jakopin NE, Garzon A, Gross P, Holubkov R, Tamber MS, Moghekar A, Preston J, Romanoski MM, Shannon CN, van der Willigen T, Koschnitzky JE, Chau MJ.   +13 more
europepmc   +1 more source